Omalizumab Shows Promise in Treating Childhood Food Allergies

Omalizumab Shows Promise in Treating Childhood Food Allergies

repubblica.it

Omalizumab Shows Promise in Treating Childhood Food Allergies

A 10-year study shows the monoclonal antibody Omalizumab significantly improves food tolerance in children with food allergies, offering a potential new treatment avenue.

Italian
Italy
HealthLifestyleImmunotherapyMedical TreatmentPediatricsFood AllergiesClinical Research
Bambino Gesù Children's HospitalFda
Stefania ArasiAlessandro Fiocchi
How does Omalizumab work to alleviate food allergy symptoms?
The drug works by binding to free IgE antibodies, preventing allergic reactions. It's not a cure and requires regular injections, but it significantly raises the threshold for allergic reactions.
How long did the study on Omalizumab's effects on food allergies last?
A 10-year study at Bambino Gesù Children's Hospital in Italy found that over 60% of children with severe asthma treated with Omalizumab could tolerate unrestricted diets within 12 months.
What is the main finding of the study on Omalizumab and food allergies in children?
Omalizumab, a monoclonal antibody, has shown promise in helping children with food allergies tolerate previously problematic foods.
What are some limitations or considerations regarding the use of Omalizumab for food allergies?
While effective for many, Omalizumab is not a universal solution. It's costly, requires a doctor's assessment for eligibility, and its effectiveness is tied to continued use.
What were some of the key quantitative results of the study regarding increased tolerance thresholds?
The study showed that Omalizumab increased reaction thresholds by 250 times for milk and hazelnuts, 170 times for eggs, and 55 times for peanuts. Anaphylactic reactions dropped dramatically after treatment.